Chardan Capital analyst Gbola Amusa downgraded Vascular Biogenics (NASDAQ: VBLT) to Hold today and set a price target of $3. The company’s shares opened today at $2.20, close to its 52-week low of $2.00.
According to TipRanks.com, Amusa is a top 100 analyst with an average return of 30.0% and a 55.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
Currently, the analyst consensus on Vascular Biogenics is a Hold with an average price target of $3.
See today’s analyst top recommended stocks >>
Based on Vascular Biogenics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.18 million. In comparison, last year the company had a GAAP net loss of $4.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the development and commercialization of treatments for cancer and immune-inflammatory diseases. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.
